In this single-center retrospective study, 115 patients with advanced NSCLC who underwent PD-1/PD-L1 ICI with/without chemotherapy with baseline 18F-FDG PET/CT between 2018 and 2023 were enrolled. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.